pharmacopoeial standards
-
Upload
raghava-reddy -
Category
Education
-
view
1.894 -
download
0
description
Transcript of pharmacopoeial standards
![Page 1: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/1.jpg)
pharamacopoeial standards
RAGHAVA REDDY.KRATNAM INSTIUTE OF PHARMACY
NELLOR EANDHRA PRADESH
![Page 2: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/2.jpg)
10/04/2023 2
Why we need standards ?
How we can frame the standards ?
What is pharmacopoeia ?
![Page 3: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/3.jpg)
10/04/2023 3
Scientific body Subject experts Representatives of CDSCO State regulatory authorities Specialist from industries Associations ,councils...
![Page 4: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/4.jpg)
10/04/2023 4
Pharmacopoeia in its modern technical sense, is a book containing directions for the identification of samples and the preparation of compound medicines, and published by the authority of a government or a medical or pharmaceutical society.
![Page 5: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/5.jpg)
10/04/2023 5
OBJECTIVE
The overall objective has been the creation of a compilation of standards that reflect the state of the industry in the country and the production and testing capabilities of units varying in size from the small to the very big.
![Page 6: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/6.jpg)
10/04/2023 6
Priority given to monographs of drugs included in the National Essential Drugs List and their dosage forms.
Regular upgradation of monographs but consistent with the level and degree of sophistication acceptable to the majority of manufacturers.
Harmonization of IP standards with international acceptance criteria for drug quality.
![Page 7: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/7.jpg)
10/04/2023 7
QUALITY STANDARDS
A compromise between the desirable and the achievable
Retention of simple tests where complicated methods offer no advantage
No compromise on limitation of toxic impurities
Gradual tightening of standards over the years
![Page 8: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/8.jpg)
10/04/2023 8
Pharmacopoeial standards are the minimum ones
Acceptable levels of change
Strong compliance between GMP and pharmacopoeial standards
![Page 9: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/9.jpg)
10/04/2023 9
The primary focus of the pharmacopoeia has been provision of standards for licensed products
Prescribing standards for labeling and packaging
Considerable support must be given to the traditional medicines
![Page 10: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/10.jpg)
10/04/2023 10
NORMAL FORMATE
Description: Physical form of the material, whether hygroscopic, odour, and indication of polymorphism, if applicable
Identification Tests usually including infrared spectrometry, if appropriate
Non-specific purity tests, such as light absorption, optical rotation, sulphated ash etc
![Page 11: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/11.jpg)
10/04/2023 11
Impurities may result from manufacturing process or by degradation of product during storage
Impurities other than related substances that may require control such as heavy metals, inorganic impurities, residues of solvents and reagents used during synthesis and purification
![Page 12: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/12.jpg)
10/04/2023 12
Storage guidelines considering different geographical atmosphere
Other tests such as loss on drying
Assay and limits for purity calculated on the anhydrous, dried or solvent-free basis, as appropriate
![Page 13: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/13.jpg)
10/04/2023 13
The requirements given in the monographs are not framed to provide against all possible impurities, contaminants or adulterants; they provide appropriate limitation of potential impurities only.
![Page 14: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/14.jpg)
10/04/2023 14
Identification tests based on those for the parent drug substance, where applicable, with suitable details for isolation of the active ingredient from the excipients.
Impurities as in the case of drug substances but additionally including those arising on manufacture or storage of the dosage form.
![Page 15: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/15.jpg)
10/04/2023 15
TEST METHODS
Pharmacopoeial methods usually prescribe the use of testing equipment available to most manufacturers and public testing laboratories.
Test methods are described in a clear language and in sufficient detail that they can be followed in any laboratory by a trained analyst.
![Page 16: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/16.jpg)
10/04/2023 16
Decision making capacity : which monograph we have to introduce[include] or exclude.
Based on the adverse effects , indications, prevalence of the disease.
![Page 17: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/17.jpg)
10/04/2023 17
THALIDOMIDE-cons
![Page 18: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/18.jpg)
10/04/2023 18
ANTI-CANCER DRUGS-pros
They have serious adverse effects but because of their indications we have to
continue in the treatment……….
They have serious adverse effects like alopecia neurotoxicity nephrotoxicity cardiotoxicity
HERE PROS &CONS MEANS POSITIVE & NEGATIVE
![Page 19: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/19.jpg)
10/04/2023 19
Expression of terms used in pharmacopoeia should be clear…..
Ex: negligible freshly prepared cold freezing temperature
![Page 20: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/20.jpg)
10/04/2023 20
HISTORY OF IP
Process started in the year 1944 under COL sri R.N CHOPRA
First publication in the year 1946 First edition in the year 1955 1966 1985 1996 2007 2010
![Page 21: pharmacopoeial standards](https://reader033.fdocuments.net/reader033/viewer/2022061221/54be9cbe4a7959d8038b4608/html5/thumbnails/21.jpg)
10/04/2023 21
TITLE INN Chemical formula A.W&M.WCATEGORY description DOSE usual strengthIDENTIFICATION assay SOLUBILITY structure